News coverage about Auris Medical (NASDAQ:EARS) has trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Auris Medical earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.4822697778921 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Auris Medical (EARS) & Its Competitors Critical Review (americanbankingnews.com)
- Keep Your Active Eyes on Auris Medical Holding AG (EARS) with Unusual Volume Alert – Wall Street Morning (wallstreetmorning.com)
- Auris Medical Holding AG (NASDAQ:EARS) – Eye-Catching Shares – Nasdaq Journal (press release) (nasdaqjournal.com)
- Auris Medical Provides Update on AM-111 Development Program – GlobeNewswire (press release) (globenewswire.com)
Separately, Zacks Investment Research lowered shares of Auris Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th.
TRADEMARK VIOLATION WARNING: This article was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://stocknewstimes.com/2018/01/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-auris-medical-ears-share-price.html.
About Auris Medical
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.